Efficacy of Integrated Exposure Therapy vs Integrated Coping Skills Therapy for Comorbid Posttraumatic Stress Disorder and Alcohol Use Disorder: A Randomized Clinical Trial.

Sonya B Norman, Ryan Trim, Moira Haller, Brittany C Davis, Ursula S Myers, Peter J Colvonen, Erika Blanes, Robert Lyons, Emma Y Siegel, Abigail C Angkaw, Gregory J Norman, Tina Mayes
Author Information
  1. Sonya B Norman: VA San Diego Healthcare System, San Diego, California.
  2. Ryan Trim: VA San Diego Healthcare System, San Diego, California.
  3. Moira Haller: VA San Diego Healthcare System, San Diego, California.
  4. Brittany C Davis: VA San Diego Healthcare System, San Diego, California.
  5. Ursula S Myers: Ralph H. Johnson VA Medical Center, Charleston, South Carolina.
  6. Peter J Colvonen: VA San Diego Healthcare System, San Diego, California.
  7. Erika Blanes: VA San Diego Healthcare System, San Diego, California.
  8. Robert Lyons: VA San Diego Healthcare System, San Diego, California.
  9. Emma Y Siegel: Department of Psychology, University of Texas, Austin.
  10. Abigail C Angkaw: VA San Diego Healthcare System, San Diego, California.
  11. Gregory J Norman: Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla.
  12. Tina Mayes: VA San Diego Healthcare System, San Diego, California.

Abstract

Importance: Co-occurrence of posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) is common and associated with psychiatric and functional problems. Understanding whether exposure therapy is tolerable and efficacious for treating PTSD and AUD is critical to ensure that best practice treatments are available.
Objective: To compare the efficacy of integrated (ie, targeting both PTSD and alcohol use) prolonged exposure (I-PE) therapy with present-centered integrated coping skills (I-CS) therapy, a more commonly available treatment, in reducing PTSD symptoms and alcohol use.
Design, Setting, and Participants: This prospective randomized clinical trial with masked assessments considered 186 veterans seeking Veterans Affairs mental health services. A total of 119 veterans with PTSD and AUD were randomized. Data were collected from February 1, 2013, to May 31, 2017, before treatment, after treatment, and at 3- and 6-month follow-ups. Intention-to-treat analyses were performed.
Interventions: Veterans underwent I-PE (Concurrent Treatment of PTSD and Substance Use Disorder Using Prolonged Exposure) or I-CS (Seeking Safety) therapy.
Main Outcomes and Measures: A priori planned outcomes were PTSD symptoms (Clinician Administered PTSD Scale for DSM-5) and percentage of heavy drinking days (Timeline Follow-Back) before treatment, after treatment, and at 3- and 6-month follow-ups.
Results: A total of 119 veterans (mean [SD] age, 41.6 [12.6] years; 107 [89.9%] male) were randomized. Linear mixture models found that PTSD symptoms decreased in both conditions, with a significantly greater decrease for I-PE treatment compared with I-CS treatment (treatment × time interaction, -2.83; F3,233.1 = 4.92; Cohen d = 0.41; P = .002). The percentage of heavy drinking days improved in both conditions but was not statistically different between I-PE and I-CS treatment (treatment × time interaction, 1.8%; F3,209.9 = 0.18; Cohen d = 0.04; P = .91).
Conclusions and Relevance: The I-PE arm had a greater reduction in PTSD symptoms than the I-CS arm and comparable drinking decreases. The study provides evidence that exposure therapy is more efficacious in treating PTSD than a more commonly available integrated treatment without exposure for comorbid PTSD and AUD.
Trial Registration: ClinicalTrials.gov identifier: NCT01601067.

Associated Data

ClinicalTrials.gov | NCT01601067

References

  1. Psychother Psychosom. 2017;86(3):150-161 [PMID: 28490022]
  2. Drug Alcohol Depend. 2011 Jul 1;116(1-3):93-101 [PMID: 21277712]
  3. J Subst Abuse Treat. 1998 Nov-Dec;15(6):499-504 [PMID: 9845863]
  4. J Clin Psychiatry. 2013 Jun;74(6):e541-50 [PMID: 23842024]
  5. J Psychoactive Drugs. 2014 Oct-Dec;46(4):295-302 [PMID: 25188699]
  6. J Addict Med. 2017 Mar/Apr;11(2):119-125 [PMID: 28079572]
  7. J Affect Disord. 2018 Jul;234:256-260 [PMID: 29550742]
  8. Am J Psychiatry. 2010 Jan;167(1):95-101 [PMID: 19917596]
  9. Addict Behav. 2004 Nov;29(8):1665-72 [PMID: 15451135]
  10. JAMA Psychiatry. 2017 Jan 01;74(1):28-36 [PMID: 27893032]
  11. Ann Intern Med. 2000 Jul 4;133(1):21-30 [PMID: 10877736]
  12. Alcohol Clin Exp Res. 2008 Mar;32(3):481-8 [PMID: 18215214]
  13. Biochem Med (Zagreb). 2012;22(3):276-82 [PMID: 23092060]
  14. J Subst Abuse Treat. 2007 Jul;33(1):25-32 [PMID: 17588486]
  15. J Clin Psychiatry. 2011 Aug;72(8):1072-8 [PMID: 21899816]
  16. J Psychoactive Drugs. 2014 Oct-Dec;46(4):303-9 [PMID: 25188700]
  17. J Subst Abuse Treat. 2016 Mar;62:38-48 [PMID: 26718130]
  18. Am J Addict. 2011 Sep-Oct;20(5):412-9 [PMID: 21838839]
  19. Drug Alcohol Depend. 1996 Sep;42(1):49-54 [PMID: 8889403]
  20. Arch Gen Psychiatry. 2005 Jun;62(6):617-27 [PMID: 15939839]
  21. J Consult Clin Psychol. 1999 Apr;67(2):194-200 [PMID: 10224729]
  22. J Psychoactive Drugs. 2007 Sep;39(3):231-40 [PMID: 18159776]
  23. J Subst Abuse Treat. 2001 Jul;21(1):47-54 [PMID: 11516926]
  24. Behav Res Ther. 2004 Mar;42(3):277-92 [PMID: 14975770]
  25. Clin Psychol Rev. 2015 Jun;38:25-38 [PMID: 25792193]
  26. Addict Behav. 2019 Mar;90:369-377 [PMID: 30529244]
  27. Eur J Psychotraumatol. 2012;3: [PMID: 22893847]
  28. J Subst Abuse Treat. 1999 Jul-Sep;17(1-2):3-14 [PMID: 10435248]
  29. Eval Program Plann. 1982;5(3):233-7 [PMID: 10259963]
  30. Psychol Assess. 2018 Mar;30(3):383-395 [PMID: 28493729]
  31. J Consult Clin Psychol. 2018 Oct;86(10):810-819 [PMID: 30265040]
  32. Addict Behav. 2006 Feb;31(2):351-4 [PMID: 15951125]
  33. Contemp Clin Trials. 2015 May;42:244-51 [PMID: 25933919]
  34. JAMA. 2012 Aug 15;308(7):690-9 [PMID: 22893166]
  35. Addict Behav. 2014 Feb;39(2):420-7 [PMID: 24035644]
  36. Drug Alcohol Depend. 2019 Jan 1;194:6-12 [PMID: 30390551]

Grants

  1. T32 AA013525/NIAAA NIH HHS

MeSH Term

Adaptation, Psychological
Adult
Alcoholism
Cognitive Behavioral Therapy
Comorbidity
Female
Follow-Up Studies
Humans
Implosive Therapy
Male
Middle Aged
Outcome Assessment, Health Care
Stress Disorders, Post-Traumatic
United States
United States Department of Veterans Affairs
Veterans